Cencora (NYSE:COR) Updates FY 2026 Earnings Guidance

Cencora (NYSE:COR) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 17.700-17.900 for the period, compared to the consensus EPS estimate of 17.760. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on COR. Weiss Ratings cut Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. Barclays reduced their price target on Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Wells Fargo & Company dropped their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Finally, Robert W. Baird reduced their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Cencora Trading Up 1.1%

Shares of COR stock opened at $287.55 on Friday. Cencora has a 1-year low of $244.82 and a 1-year high of $377.54. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The stock has a market cap of $55.95 billion, a price-to-earnings ratio of 22.05, a PEG ratio of 1.53 and a beta of 0.59. The stock has a 50-day moving average of $281.44 and a 200-day moving average of $322.43.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities research analysts forecast that Cencora will post 17.79 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.8%. Cencora’s payout ratio is presently 18.40%.

Cencora announced that its Board of Directors has approved a share buyback plan on Thursday, May 21st that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 3.9% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In other Cencora news, Director Lauren M. Tyler acquired 550 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were bought at an average cost of $270.23 per share, with a total value of $148,626.50. Following the purchase, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.38% of the company’s stock.

Institutional Trading of Cencora

Several large investors have recently modified their holdings of the stock. State Street Corp boosted its stake in Cencora by 1.3% during the fourth quarter. State Street Corp now owns 9,305,507 shares of the company’s stock worth $3,142,935,000 after acquiring an additional 115,191 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Cencora by 80.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,661,769 shares of the company’s stock valued at $1,574,513,000 after purchasing an additional 2,085,473 shares during the period. Wellington Management Group LLP boosted its position in shares of Cencora by 14.2% during the 4th quarter. Wellington Management Group LLP now owns 4,535,992 shares of the company’s stock worth $1,532,031,000 after purchasing an additional 564,871 shares in the last quarter. Boston Partners grew its stake in shares of Cencora by 2.0% in the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company’s stock valued at $1,409,152,000 after buying an additional 89,506 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Cencora by 5.9% in the 3rd quarter. Northern Trust Corp now owns 2,272,464 shares of the company’s stock valued at $710,213,000 after buying an additional 126,929 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.